CervoMed Inc. 8-K

What Happened
CervoMed Inc. announced on June 18, 2026 that it entered into a Securities Purchase Agreement to sell 2,500,000 shares of common stock at $4.00 per share in a registered direct offering for gross proceeds of $10.0 million (expected to close on or about June 22, 2026). The shares are being offered under the company’s effective Form S-3 registration statement. The company said net proceeds will be used for working capital and general corporate purposes and issued a press release the same day announcing the pricing.

Key Details

• Offering: 2,500,000 shares at $4.00 per share for $10.0 million gross proceeds.
• Placement agent: H.C. Wainwright & Co., engaged June 16, 2026; cash fee = 6.0% of gross proceeds plus placement agent warrants equal to 6.0% of shares issued.
• Placement Agent Warrants: immediately exercisable, 5‑year term, $5.00 exercise price ($4.999 if issued as pre-funded); default beneficial ownership cap 4.99% (can be adjusted up to 9.99% after 61 days). Pre-funded warrants (if used) have $0.001 exercise price and no expiration.
• Fees/expenses: additional management fee 1.0% of gross proceeds, non-accountable expenses $35,000, up to $50,000 for placement agent legal fees, and $15,950 clearing expenses.
• Restrictions: 30-day lock-up on issuing or announcing new shares or equivalents and a six-month restriction on variable rate transactions, subject to customary exceptions.
• Legal: Mintz Levin issued an opinion on the legality of the share issuance; Placement Agent Warrants were not registered under the Securities Act.

Why It Matters
This financing provides CervoMed with near-term capital for operations and corporate needs, which can reduce short-term funding risk. However, the offering and the attached placement agent warrants create potential dilution for existing shareholders if the warrants or pre-funded warrants are exercised. The placement agent warrants are not listed and may have limited liquidity. Investors should note the timing (expected close ~June 22, 2026), the immediate exercisability and five-year term of the warrants, and the company’s stated use of proceeds when assessing impact on share count and near-term financial position.